-
Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5' inositol phosphatase (SHIP).
J Exp Med. 2000 May 1;191(9):1545-54
PMID: 10790429
-
Future directions with hematopoietic growth factors.
J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S96-101
PMID: 19795582
-
Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein.
Blood. 2001 Oct 1;98(7):2028-38
PMID: 11567986
-
Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation.
Science. 2002 Mar 15;295(5562):2094-7
PMID: 11896280
-
SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts.
Nat Med. 2002 Sep;8(9):943-9
PMID: 12161749
-
Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity.
Comb Chem High Throughput Screen. 2003 Jun;6(4):321-30
PMID: 12769675
-
Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy.
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S39-47
PMID: 14563520
-
The allograft response.
Surg Clin North Am. 1986 Dec;66(6):1231-53
PMID: 3097848
-
Stimulation of mature unprimed CD8+ T cells by semiprofessional antigen-presenting cells in vivo.
J Exp Med. 1992 Nov 1;176(5):1291-302
PMID: 1402675
-
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Blood. 1996 Sep 1;88(5):1542-50
PMID: 8781408
-
Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.
Science. 1997 Jan 31;275(5300):665-8
PMID: 9005852
-
SHIP, a new player in cytokine-induced signalling.
Leukemia. 1997 Feb;11(2):181-4
PMID: 9009077
-
Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span.
Genes Dev. 1998 Jun 1;12(11):1610-20
PMID: 9620849
-
The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling.
J Exp Med. 1998 Oct 5;188(7):1333-42
PMID: 9763612
-
SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival.
Genes Dev. 1999 Apr 1;13(7):786-91
PMID: 10197978
-
Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
Science. 1999 Jul 16;285(5426):412-5
PMID: 10411505
-
Growth characteristics of free C1498 granulocytic leukemia tumor cells in the peritoneal fluid and the blood of C57 mice.
Cancer Res. 1953 Feb;13(2):125-9
PMID: 13042796
-
Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses.
J Immunol. 2004 Dec 15;173(12):7324-30
PMID: 15585856
-
Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells.
J Immunol. 2005 Feb 15;174(4):1841-50
PMID: 15699110
-
Thrombopoietic growth factors and cytokines.
Curr Hematol Rep. 2005 Mar;4(2):137-44
PMID: 15720963
-
SHIP represses the generation of alternatively activated macrophages.
Immunity. 2005 Oct;23(4):361-74
PMID: 16226502
-
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.
Nature. 2006 May 25;441(7092):475-82
PMID: 16598206
-
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.
Nature. 2006 May 25;441(7092):518-22
PMID: 16633340
-
Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets.
J Immunol. 2006 Jun 15;176(12):7165-9
PMID: 16751359
-
Induced SHIP deficiency expands myeloid regulatory cells and abrogates graft-versus-host disease.
J Immunol. 2007 Mar 1;178(5):2893-900
PMID: 17312133
-
Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell.
J Immunol. 2007 Dec 15;179(12):8009-15
PMID: 18056340
-
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover.
Carcinogenesis. 2008 Jan;29(1):25-34
PMID: 17893231
-
A role for SHIP in stem cell biology and transplantation.
Curr Stem Cell Res Ther. 2008 May;3(2):99-106
PMID: 18473876
-
PI3K pathway alterations in cancer: variations on a theme.
Oncogene. 2008 Sep 18;27(41):5497-510
PMID: 18794884
-
SH2-inositol phosphatase 1 negatively influences early megakaryocyte progenitors.
PLoS One. 2008;3(10):e3565
PMID: 18958162
-
High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival.
Tumour Biol. 2008;29(5):330-41
PMID: 19065064
-
SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells.
Int J Oncol. 2009 Jan;34(1):97-105
PMID: 19082482
-
SHIP is required for a functional hematopoietic stem cell niche.
Blood. 2009 Mar 26;113(13):2924-33
PMID: 19074735
-
SHIP limits immunoregulatory capacity in the T-cell compartment.
Blood. 2009 Mar 26;113(13):2934-44
PMID: 19136659
-
Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1.
EMBO Rep. 2009 May;10(5):487-93
PMID: 19325558
-
Intracellular delivery of phosphoinositides and inositol phosphates using polyamine carriers.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11286-91
PMID: 11005844